UCART22 not checked

Cellectis S.A.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
None yet
 
Trials
1 active
1 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen”In the company’s words, NCT04150497 on ClinicalTrials.gov
Tested for
B-cell Acute Lymphoblastic Leukemia
Main trialPhase 1/2
“This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to determine the optimal dose of CLLS52 as part of the FCA LD regimen followed by the Recommended Phase 2 Dose (RP2D) of UCART22 and evaluate the safety and efficacy of UCART22.”In the company’s words, NCT04150497 on ClinicalTrials.gov

Other drugs for B-cell Acute Lymphoblastic Leukemia

All 31 drugs for B-cell Acute Lymphoblastic Leukemia

Coming up0

No dates coming up.

Changes2

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Active, not recruiting 16 Sep 2026 Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow UCART22

Following is part of Solo: you see every change to UCART22 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in